A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Jun 2018
At a glance
- Drugs Dupilumab (Primary) ; Mometasone
- Indications Nasal polyps
- Focus Therapeutic Use
- Acronyms SINUS-52
- Sponsors Sanofi
- 03 May 2018 According to a Regeneron media release, data from this trial is expected to be reported during 2018.
- 18 Dec 2017 Planned primary completion date changed from 19 Nov 2018 to 27 Aug 2018.
- 20 Nov 2017 Status changed from recruiting to active, no longer recruiting.